# Percentage of susceptible Organisms Isolated From Blood, RMSc 10, 3 hospitals, Jan - Jun 2018

| | Organism | TOTAL ISOLATES | BETA LACTAMS | | | | | | | | | | | | | | | CARBAPENEMS | | | POLY MYXINS | | | | | AMINOGLYCOSIDES | | | | GLYCOPEPTIDES | | | MISCELLANEOUS | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | PENICILLIN | PENICILLIN BY MIC | AMPICILLIN | AMOXICILLIN/CLAVULANIC ACID | AMPICILLIN / SULBACTAM | PIPERACILLIN / TAZOBACTAM | CEFAZOLIN (A) | CEFUROXIME SODIUM (parenteral) | CEFOPERAZONE / SULBACTAM [a] | CEFOTAXIME | CEFTAZIDIME | CEFTRIAXONE | CEFEPIME | OXACILLIN | CEFOXITIN | ERTAPENEM | IMIPENEM | MEROPENEM | COLISTIN BY MIC | CIPROFLOXACIN | CIPROFLOXACIN BY MIC | LEVOFLOXACIN | OFLOXACIN | AMIKACIN | GENTAMICIN | GENTAMICIN 120 µg | NETILMICIN | VANCOMYCIN | VANCOMYCIN BY MIC | TEICOPLANIN | CLINDAMYCIN | CLINDAMYCIN BY MIC | ERYTHROMYCIN | ERYTHROMYCIN BY MIC | CHLORAMPHENICOL | COTRIMOXAZOLE | TETRACYCLINE |
| Gram negati | *Acinetobacter calcoaceticus-baumannii* complex | 81 | | | R | R | - | - | | | | 1.6 (61) | 27.2 (81) | 5.6 (72) | - | | | R | 35.1 (74) | 57.9 (38) | - [e] | 36 (75) | | - | | 49.4 (77) | 41.3 (75) | | | | | | | | | | R | 45.3 (75) | |
| | *Escherichia coli* | 368 | | | 16.8 (179) | 69 (342) | - | - | - | 54.5 (178) | 91.8 (219) | 60.1 (366) | 68.2 (368) | 56.1 (198) | - | | 91.6 (178) | - | 97.7 (307) | 98.5 (206) | - [WT] | 57.5 (325) | | - | - | 99.4 (322) | 70.1 (345) | | 93.3 (178) | | | | | | | | - | 37 (324) | - |
| | *Klebsiella pneumoniae* | 134 | | | R | 64.1 (128) | - | - | - | 44.2 (86) | 64.3 (98) | 59 (134) | 61.9 (134) | 50 (92) | - | | 88.4 (86) | - | 95.7 (117) | 98.4 (62) | - [WT] | 67.2 (122) | | - | - | 95.9 (122) | 92.1 (126) | | 91.9 (86) | | | | | | | | - | 61.5 (122) | - |
| Gram positive | *Enterococcus faecalis* | 47 | 91.3 (46) | - | 92.9 (42) | | | | R | R | R | R | R | R | R | | | | | | | | | | | R | R | 76.7 [h] (30) | R | 97.9 (47) | - | - | R | R | 16.7 (36) | - | 71 (31) | R | |
| | *Enterococcus faecium* | 43 | 30.2 (43) | - | 27.9 (43) | | | | R | R | R | R | R | R | R | | | | | | | | | | | R | R | 65.8 [h] (38) | R | 92.9 (42) | - | - | R | R | 15.4 (39) | - | 97.4 (38) | R | |
| | *Staphylococcus aureus* (all isolates) | 85 | - | - | | | | | | | | | | | | 92.6 [f] (81) | | | | | | - | - | - | - | | - | | | | - | - [e] | 84.3 (83) | | 83.1 (83) | - | - | 97.6 (82) | - |
| | (MSSA) | 75 | - | - | | | | | | | | | | | | 100 [f] (75) | | | | | | - | - | - | - | | - | | | | - | - [e] | 92 (75) | | 90.7 (75) | - | - | 100 (75) | - |
| | *Staphylococcus,* coagulase negative | 274 | 3.3 (30) | - | | | | | | | | | | | | 37.7 [f] (244) | | | | | | - | - | - | - | | - | | | | - | - [e] | 39.8 (256) | | 33.6 (256) | - | - | 55.7 (244) | - |
| | (MRCNS) | 154 | - | - | | | | | | | | | | | | 0 [f] (154) | | | | | | - | - | - | - | | - | | | | - | - [e] | 13 (154) | | 7.8 (154) | - | - | 35.7 (154) | - |
| | (MSCNS) | 93 | - | - | | | | | | | | | | | | 100 [f] (93) | | | | | | - | - | - | - | | - | | | | - | - [e] | 80.6 (93) | | 76.3 (93) | - | - | 89.2 (93) | - |
| | *Streptococcus pneumoniae* | 37 | - [d] | - | | - [e] | | | | | | | | | | | | | | | | | | - | - | | | | | - | | | 69.7 (33) | | 69.7 (33) | - | - | - | - |
| | *Streptococcuss* spp. Viridans Group | 59 | 30.2 [i] (53) | - [i] | - [e] | | | | | | | - | | - | - | | | | | | | | | - | - | | | | | 97.8 (46) | | | 66 (50) | | 66 (50) | - | - | | - |

[a] : No CLSI Interpretive Criteria. Interprete according to cefoperazone/sulbactam in *Enterobacteriacae*

[b] : Blood, Pleural Fluid

[c] : Sputum, Ear, Sinus

[d] : Interprete according to oxacillin susceptibility test

[e] : MIC Interpretive Criteria

[i] : MIC Interpretive Criteria, For the 20% nonsusceptible, 15% were intermediate (MIC 0.25 to 2µg/mL) and 5% were resistant (MIC ≥ 4 µg/mL) to penicillin.